Type 2 Diabetes Care portfolio
According to IQVIA, the global insulin market value grew at a compound average growth rate (or CAGR) of 16.8% from November 2012 to November 2017.
On the other hand, the global insulin market grew at a CAGR of 4.4% based on volume in the same timeframe.
In November 2012, fast-acting insulin, premixed insulin, and long-acting insulin accounted for 34%, 29%, and 37% of global insulin market volume, respectively. In November 2017, fast-acting insulin, premixed insulin, and long-acting insulin accounted for 35%, 26%, and 40% of global insulin market volume, respectively.
Novo Nordisk (NVO) has developed a broad portfolio made up of all different types of insulin across three generations. In the human insulin segment, the company has products such as Insulatard, Mixtard, and Actrapid. In the modern insulin segment, Novo Nordisk has products such as Levemir, NovoMix, and NovoLog. In the new-generation insulin segment, the company has products such as Tresiba, Ryzodeg, Xultophy, and Fiasp.
Novo Nordisk has developed multiple diabetes care products to cater to different types of patient needs. The company has basal insulin products such as Insulatard, Levemir, and Tresiba in its portfolio for long-term glycemic control in type 2 diabetes patients. For patients for whom basal insulin does not generate the appropriate response, the company offers Xultophy, a GLP-1 and basal insulin combination, which is a once-daily optimized therapy for type 2 diabetes patients.
Additionally, Novo Nordisk also has multiple mealtime insulin control products that are further differentiated as mix insulin and bolus insulin. Mix insulin products in Novo Nordisk’s portfolio include Ryzodeg, Mixtard, and NovoMix, while bolus insulin products in the company’s portfolio include brands such as Fiasp, NovoLog, and Actrapid.
In the next article, we’ll discuss growth trends in the global insulin market in greater detail.